Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
SEK 3.84
(-2.04%)
SEK 3.84
(-2.04%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -14.87 Million SEK | -173.54% |
| 2022 | 20.22 Million SEK | 1512.01% |
| 2021 | -1.43 Million SEK | -1917.39% |
| 2020 | 78.83 Thousand SEK | 107.29% |
| 2019 | -1.08 Million SEK | -208.27% |
| 2018 | 999.4 Thousand SEK | 787.57% |
| 2017 | -145.35 Thousand SEK | 97.63% |
| 2016 | -6.12 Million SEK | -139.64% |
| 2015 | -2.55 Million SEK | 86.28% |
| 2014 | -18.63 Million SEK | -38.73% |
| 2013 | -13.42 Million SEK | -93.31% |
| 2012 | -6.94 Million SEK | -233.11% |
| 2011 | -2.08 Million SEK | 19.13% |
| 2010 | -2.57 Million SEK | -134.03% |
| 2009 | -1.1 Million SEK | 44.33% |
| 2008 | -1.97 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -15.19 Million SEK | -2.16% |
| 2024 Q3 | -15.35 Million SEK | -31.36% |
| 2024 Q2 | -11.51 Million SEK | 24.23% |
| 2023 Q1 | 23.49 Million SEK | 16.13% |
| 2023 Q4 | -14.87 Million SEK | 50.4% |
| 2023 FY | -14.87 Million SEK | -173.54% |
| 2023 Q3 | -29.99 Million SEK | -175.96% |
| 2023 Q2 | 39.48 Million SEK | 68.1% |
| 2022 Q1 | -3.33 Million SEK | -132.65% |
| 2022 Q4 | 20.22 Million SEK | 183.18% |
| 2022 Q3 | -24.32 Million SEK | -421.57% |
| 2022 FY | 20.22 Million SEK | 1512.01% |
| 2022 Q2 | -4.66 Million SEK | -39.9% |
| 2021 Q1 | -10.44 Million SEK | -13350.03% |
| 2021 Q3 | -40.42 Million SEK | 26.21% |
| 2021 Q4 | -1.43 Million SEK | 96.46% |
| 2021 FY | -1.43 Million SEK | -1917.39% |
| 2021 Q2 | -54.78 Million SEK | -424.47% |
| 2020 Q3 | -179 Thousand SEK | 90.93% |
| 2020 FY | 78.83 Thousand SEK | 107.29% |
| 2020 Q1 | -8.01 Million SEK | -640.98% |
| 2020 Q2 | -1.97 Million SEK | 75.38% |
| 2020 Q4 | 78.83 Thousand SEK | 144.04% |
| 2019 FY | -1.08 Million SEK | -208.27% |
| 2019 Q2 | -1.13 Million SEK | -2290.38% |
| 2019 Q3 | 8.59 Million SEK | 854.17% |
| 2019 Q4 | -1.08 Million SEK | -112.6% |
| 2019 Q1 | 52 Thousand SEK | -94.8% |
| 2018 Q1 | 1.07 Million SEK | 842.86% |
| 2018 Q4 | 999.4 Thousand SEK | 43.35% |
| 2018 Q3 | 697.17 Thousand SEK | 102.28% |
| 2018 Q2 | -30.64 Million SEK | -2938.06% |
| 2018 FY | 999.4 Thousand SEK | 787.57% |
| 2017 Q2 | -8.09 Million SEK | 63.06% |
| 2017 Q1 | -21.92 Million SEK | -257.99% |
| 2017 FY | -145.35 Thousand SEK | 97.63% |
| 2017 Q4 | -145.35 Thousand SEK | 98.94% |
| 2017 Q3 | -13.7 Million SEK | -69.18% |
| 2016 FY | -6.12 Million SEK | -139.64% |
| 2016 Q4 | -6.12 Million SEK | 44.63% |
| 2016 Q1 | -19.65 Million SEK | -669.07% |
| 2016 Q3 | -11.06 Million SEK | 0.74% |
| 2016 Q2 | -11.14 Million SEK | 43.3% |
| 2015 Q1 | -12.11 Million SEK | 34.99% |
| 2015 FY | -2.55 Million SEK | 86.28% |
| 2015 Q4 | -2.55 Million SEK | 65.38% |
| 2015 Q3 | -7.38 Million SEK | 35.54% |
| 2015 Q2 | -11.45 Million SEK | 5.45% |
| 2014 Q2 | -5.91 Million SEK | 43.47% |
| 2014 Q4 | -18.63 Million SEK | -789.61% |
| 2014 Q3 | -2.09 Million SEK | 64.58% |
| 2014 FY | -18.63 Million SEK | -38.73% |
| 2014 Q1 | -10.45 Million SEK | 22.11% |
| 2013 Q3 | 2.84 Million SEK | 412.05% |
| 2013 Q4 | -13.42 Million SEK | -571.8% |
| 2013 FY | -13.42 Million SEK | -93.31% |
| 2013 Q1 | -3.07 Million SEK | 55.67% |
| 2013 Q2 | 555.86 Thousand SEK | 118.05% |
| 2012 FY | -6.94 Million SEK | -233.11% |
| 2012 Q4 | -6.94 Million SEK | -29.13% |
| 2012 Q2 | -7.8 Million SEK | 1.27% |
| 2012 Q3 | -5.37 Million SEK | 31.11% |
| 2012 Q1 | -7.9 Million SEK | -279.26% |
| 2011 Q3 | -4.3 Million SEK | 32.71% |
| 2011 Q4 | -2.08 Million SEK | 51.53% |
| 2011 Q1 | -7.96 Million SEK | -209.03% |
| 2011 FY | -2.08 Million SEK | 19.13% |
| 2011 Q2 | -6.39 Million SEK | 19.77% |
| 2010 Q4 | -2.57 Million SEK | 33.0% |
| 2010 Q1 | -6.82 Million SEK | -519.81% |
| 2010 Q2 | -5.7 Million SEK | 16.42% |
| 2010 FY | -2.57 Million SEK | -134.03% |
| 2010 Q3 | -3.84 Million SEK | 32.57% |
| 2009 Q3 | -2.29 Million SEK | 34.19% |
| 2009 FY | -1.1 Million SEK | 44.33% |
| 2009 Q4 | -1.1 Million SEK | 52.08% |
| 2009 Q2 | -3.49 Million SEK | 0.0% |
| 2008 Q4 | -1.97 Million SEK | 0.0% |
| 2008 FY | -1.97 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 57.674% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 101.213% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 101.213% |
| Arcoma AB | -1.12 Million SEK | -1218.883% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 113.539% |
| BICO Group AB (publ) | 927.9 Million SEK | 101.603% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 111.55% |
| CellaVision AB (publ) | -56.94 Million SEK | 73.873% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -75.951% |
| C-Rad AB (publ) | -127.6 Million SEK | 88.341% |
| Duearity AB (publ) | 10.23 Million SEK | 245.411% |
| Dignitana AB (publ) | 13.07 Million SEK | 213.765% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 71.77% |
| Getinge AB (publ) | 5.4 Billion SEK | 100.275% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 57.559% |
| Iconovo AB (publ) | -10.75 Million SEK | -38.322% |
| Integrum AB (publ) | -10.47 Million SEK | -42.003% |
| Luxbright AB (publ) | -13.83 Million SEK | -7.544% |
| Mentice AB (publ) | -49.56 Million SEK | 69.984% |
| OssDsign AB (publ) | -162.78 Million SEK | 90.861% |
| Paxman AB (publ) | -11.41 Million SEK | -30.374% |
| Promimic AB (publ) | -50.32 Million SEK | 70.437% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 178.013% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 45.553% |
| ScandiDos AB (publ) | -1.53 Million SEK | -871.718% |
| Sectra AB (publ) | -772.85 Million SEK | 98.075% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 93.443% |
| Senzime AB (publ) | -139.54 Million SEK | 89.339% |
| SpectraCure AB (publ) | -50.23 Million SEK | 70.385% |
| Stille AB | -178.5 Million SEK | 91.666% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 101.211% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 93.069% |